Tauvid has been approved by the US Food and Drug Administration (FDA) in 2020 for
positron emission tomography (PET) imaging of adult patients with cognitive impairments …

In this review, we summarize the current knowledge on sex differences in dementia with
Lewy bodies (DLB) relating to epidemiology, clinical features, neuropathology, biomarkers …

Several advances in fluid and tissue-based biomarkers for use in Parkinson's disease (PD)
and other synucleinopathies have been made in the last several years. While work …

BackgroundBlood biomarkers of Alzheimer's disease (AD) may allow for the early detection
of AD pathology in mild cognitive impairment (MCI) due to AD (MCI-AD) and as a co …

Mild cognitive impairment with the core clinical features of dementia with Lewy bodies is
recognized as a prodromal stage of dementia with Lewy bodies. Although grey matter …

Dementia with Lewy bodies (DLB) is clinically defined by the presence of visual
hallucinations, fluctuations, rapid eye movement (REM) sleep behavioral disorder, and …

Clinical trials in dementia with Lewy bodies: the evolving c... : Current Opinion in Neurology
Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient …

Studies on dementia with Lewy bodies (DLB) have mainly focused on the degeneration of
distinct cortical and subcortical regions related to the deposition of Lewy bodies. In view of …

Dementia with Lewy bodies (DLB) is a clinical diagnosis representing a specific
presentation of a pathological α-synucleinopathy (Lewy body disease). DLB is one entity …

Parkinson's disease (PD) is the second most common neurodegenerative disease after
Alzheimer's disease (AD). Both diseases share common clinical and pathological features …